Literature DB >> 11298536

The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.

K E Harman1, P T Seed, M J Gratian, B S Bhogal, S J Challacombe, M M Black.   

Abstract

BACKGROUND: Pemphigus vulgaris (PV) and foliaceus (PF) are characterized by antibodies to the desmosomal proteins desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1), respectively. Past studies using indirect immunofluorescence (IIF) as a measure of pemphigus antibody levels have failed to demonstrate consistently a relationship between disease severity and IIF titres. However, IIF is not able to measure separately Dsg1 and 3 antibodies, unlike enzyme-linked immunosorbent assays (ELISA), which utilize recombinant proteins.
OBJECTIVES: To compare independently Dsg1 and 3 antibody levels with the severity of both cutaneous and oral involvement in PV and PF. Patients and methods Four hundred and twenty-four serum samples were analysed from 80 subjects with PV and 24 with PF. IgG antibodies to Dsg1 and 3 were measured by ELISA. For every sample analysed, the associated severity of skin and oral disease were graded from 0 to 3; quiescent, mild, moderate and severe.
RESULTS: A relationship between Dsg1 antibodies and skin severity was demonstrated such that a 10-unit increase in Dsg1 ELISA value was associated with a 34% chance of having a higher severity score [95% confidence interval (CI), 25-45%, P < 0.0005]. This was observed in both PV and PF. Oral severity was associated with Dsg3 antibody levels and a 10-unit increase in the Dsg3 ELISA value was associated with a 25% chance of a higher oral severity score (CI 17-33%, P < 0.0005). We were unable to demonstrate a relationship between Dsg1 antibodies and oral severity, even after adjusting for the effect of Dsg3 antibodies. Similarly, there was no relationship between Dsg3 antibodies and skin severity.
CONCLUSIONS: This study suggests that the clinical phenotype of pemphigus, in particular the balance of skin and oral disease, is determined principally by the quantities of Dsg1 and 3 autoantibodies, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298536     DOI: 10.1046/j.1365-2133.2001.04132.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  43 in total

1.  A novel method to investigate pemphigus-induced keratinocyte dysmorphisms through living cell immunofluorescence microscopy.

Authors:  Nicola Cirillo; Felice Femiano; Antonio Dell'Ermo; Pietro Arnese; Fernando Gombos; Alessandro Lanza
Journal:  Virchows Arch       Date:  2007-04-21       Impact factor: 4.064

Review 2.  Pemphigus: a brief review.

Authors:  Richard W Groves
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

3.  Pemphigus vulgaris localized to the tongue.

Authors:  Tegan Nguyen; Abdul Razzaque Ahmed
Journal:  J Dermatol Case Rep       Date:  2014-06-30

Review 4.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

5.  Elevated expression of NLRP1 and IPAF are related to oral pemphigus vulgaris pathogenesis.

Authors:  Reza Mahvelati Shamsabadi; Soroush Basafa; Reza Yarahmadi; Samaneh Goorani; Masood Khani; Maryam Kamarehei; Amir Hossein Kiani
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

6.  Effects of L-carnitine supplementation on biomarkers of oxidative stress, antioxidant capacity and lipid profile, in patients with pemphigus vulgaris: a randomized, double-blind, placebo-controlled trial.

Authors:  H Mohammadi; M Djalali; M Daneshpazhooh; N M Honarvar; C Chams-Davatchi; F Sepandar; Z Fakhri; E Yaghubi; M Zarei; M H Javanbakht
Journal:  Eur J Clin Nutr       Date:  2017-08-23       Impact factor: 4.016

Review 7.  Severity score indexes for blistering diseases.

Authors:  Benjamin S Daniel; Michael Hertl; Victoria P Werth; Rüdiger Eming; Dédée F Murrell
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 8.  Pemphigus.

Authors:  Frank A Santoro; Eric T Stoopler; Victoria P Werth
Journal:  Dent Clin North Am       Date:  2013-08-12

9.  Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up.

Authors:  Anna Belloni-Fortina; Diana Faggion; Barbara Pigozzi; Andrea Peserico; Matteo Bordignon; Vincenzo Baldo; Mauro Alaibac
Journal:  Clin Dev Immunol       Date:  2009-12-10

10.  Pemphigus: active or inactive?

Authors:  Jignesh B Vaishnani; Sanjay S Bosamiya
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.